Immunovant (IMVT) PT Lowered to $28 at Stifel, Model Update Following Earnings
- Wall Street slips off record highs, Tesla drops after fatal crash
- IBM (IBM) Tops Q1 EPS by 14c, Revenue Beats
- Tesla's (TSLA) Musk says data logs from crashed vehicle show Autopilot was not enabled, car did not purchase FSD
- Bitcoin (BTC) Price Fell 20% Off the Highs Over the Weekend as Markets Got 'Too Excited' About Coinbase (COIN), Says Mike Novogratz
- GameStop (GME) CEO Gets the Axe as Ryan Cohen Continues to Make His Mark, Analyst Says Co. Will Likely Look to Tech Sector for New Hires
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Stifel analyst Derek C. Archila lowered the price target on Immunovant (NASDAQ: IMVT) to $28.00 (from $33.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Starbucks (SBUX) PT Raised to $135 at Oppenheimer Into Q1 Results (Earlier)
- United Rentals (URI) PT Raised to $375 at Stifel, Following Strategic Business Update
- Ambuja Cements Ltd. (ACEM:IN) PT Raised to INR380 at Citi
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesStifel, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!